Learn How Wall Street is Using AI to Profit https://felixfriends.org/training
3 extracted signals · 2 resolved · 1 still active
Felix & Friends (Goat Academy)Independent analyst profile- Source published
- 06 Oct 2025, 17:00 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:23 UTC
AI-generated source summary
The video analyzes four stocks: CLSK, ORIC, REGN, and LAR, across crypto mining, biotech, pharma, and lithium sectors. CleanSpark (CLSK), a Bitcoin mining play, has $344 million in revenue and is trading at $15.94 with Wall Street predicting to $20. Entry strategy involves waiting for a pullback towards $15, buying on the rally or a breakout at $16.50. Oric Pharmaceuticals (ORIC) trades at $11.57 with an average price target to $17.29. Regeneron Pharmaceuticals (REGN) is $600 and with a blockbuster drug seeing a recent approval for a new market, with a price target of $1053. Lithium Argentina(LAR) , at just 0.36 times book value with a price target of $1 with an entry strategy. The model advises using a balanced approach, allocating a quarter of resources to each asset, and setting stop losses (10-20% range) to manage risk and it does not give a precise stop for this ticker.
AI-generated summary based on the source content.
Signal outcomes at a glance
Partially ResolvedSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
3 eligible signals linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- Live evaluation in progress
1 signal remains active.
Felix & Friends (Goat Academy)
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.